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Introduction: Tendon injury is a major cause of lameness and decreased performance in athletic equines. Various
therapies for tendonitis have been described; however, none of these therapies results in complete tissue
regeneration, and the injury recurrence rate is high even after long recovery periods involving rest and
physiotherapy.
Methods: A lesion was induced with collagenase gel in the superficial digital flexor tendon in the center portion of
the metacarpal region of eight equines of mixed breed. After two weeks, the lesions of the animals in the treated
and control groups were treated through the intralesional administration of mesenchymal stem cells derived from
adipose tissue (adMSCs) suspended in platelet concentrate (PC) and with phosphate buffered saline (PBS),
respectively. Serial ultrasound analyses were performed every two weeks. After 16 weeks of therapy, a biopsy was
performed for histopathological, immunohistochemical and gene expression (type I collagen (COL1A1), type III
collagen (COL3A1), tenascin-C (TNC), tenomodulin (TNMD), and scleraxis (SCX)) analyses.
Results: Differences in the ultrasound and histopathological analyses were observed between the groups.
Improved results were reported in the group treated with adMSCs suspended in PC. There was no difference in the
gene expression levels observed after the different treatments. The main results observed from the
histopathological evaluation of the treated group were as follows: a prevention of the progression of the lesion, a
greater organization of collagen fibers, and a decreased inflammatory infiltrate. A lack of progression of the lesion
area and its percentage was observed in the ultrasound image, and increased blood flow was measured by
Power Doppler.
Conclusions: The use of adMSCs combined with PC for the therapy of experimentally induced tendonitis
prevented the progression of the tendon lesion, as observed in the ultrasound examination, and resulted in a
greater organization and decreased inflammation, as observed in the histopathological evaluation. These data
demonstrate the therapeutic potential of this therapy for the treatment of equine tendonitis.
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Tendon lesions are a major cause of lameness and re-
duced performance in athletic horses and may result in
the early termination of the animals’ careers [1]. Ten-
dinous structures are poorly vascularized, are relatively
acellular, and have limited potential for regeneration be-
cause the tendon repair is prolonged and results in the
formation of scar tissue, which is biomechanically infe-
rior and prone to lesion recurrence [2].
A tendon injury usually requires a considerable rest
period (from six months to over a year) to allow ad-
equate tissue repair. Conventional treatments for ten-
donitis are basically clinical and surgical approaches.
However, the recovered animals are rarely sufficiently
healed to allow their return to competitions with a
performance similar to that observed when they were
healthy [3].
Regenerative medicine has significantly evolved. In
addition, the use of mesenchymal stem cells (MSCs) and
the implantation of platelet concentrate (PC) in the ther-
apy of equine tendonitis have been previously described
[4-14]. Previous studies have shown a significant de-
crease in the recurrence rate of tendonitis for a period
of at least two years in animals treated with cell therapy
(27%) compared with those that were treated with con-
ventional therapies (56%) [15].
There are several sources of MSCs available, inclu-
ding the bone marrow, the adipose tissue, the peripheral
blood, the blood and matrix from the umbilical cord,
and the tendons [16]. Of these sources, the bone mar-
row has been considered the most important source of
MSCs. However, other sources, such as the adipose tis-
sue, exhibit interesting characteristics, such as a greater
number of viable MSCs with a high rate of migration
and cell differentiation; thus, these characteristics make
this source a convenient source of progenitor cells [17].
PC is an autologous biological product that is used in
equine sports medicine with evident clinical efficacy.
The benefits of this therapy include minimally invasive
collection and fast, easy, and low-cost processing. The
therapeutic efficacy of PC is due to the release of several
growth factors that are injected directly into the injured
area [18]. The studies that demonstrate the potential of
PC in the therapy of equine tendonitis, such as those
that analyzed the improvement of the score obtained
through the ultrasound evaluation of clinical cases [14],
showed increased local vascularization [19] and meta-
bolic activity, which resulted in the maturation of tissue
repair [12].
The suspension of MSCs in PC has been used with
promising results in bone repair [20-22]. Only one clini-
cal study in equines investigated equine tendonitis thera-
py using mesenchymal stem cells derived from adipose
tissue (adMSCs) suspended in PC [11], and 14 out of the16 animals that underwent superficial digital flexor ten-
don (SDFT) therapy returned to athletic activity.
The present study aimed to evaluate the effects of au-
tologous adMSCs suspended in autologous PC in the
therapy of animals with experimentally induced tendon-
itis through ultrasound, histopathological, immunohisto-
chemical and gene expression analyses.Methods
Animals
Eight young horses (seven females and one male) of
mixed breed and aged between three and four and a half
years were used. The animals were clinically and ultra-
sonographically examined before the start of the expe-
riment to ensure that there was no tendon injury. A
complete blood count was also performed to confirm
the health status of the animals. All of the animals were
placed in individual stalls and adapted to daily manage-
ment for 21 days before the start of the experiment. The
protocol was approved by the ethics committee for ani-
mal experimentation of the university (number: 213/
2008). In addition to the eight tendons of the horses
used in the experiment, four tendons were used that
were obtained from equines (two males and two females,
mixed breed, aged between three and eight years) that
were euthanized due to complications during surgical
procedures that did not compromise the SDFT. The
samples from euthanized horses were used to standar-
dize the quantitative reverse transcription polymerase
chain reaction (qRT-PCR) analysis. The animals’ pre-
vious histories of tendonitis were also researched to
ensure that the collected fragments were obtained
from healthy tendons.Study design
The study consisted of two randomly chosen groups: the
treated group (TG; tendon treated with adMSCs, n = 4)
and the control group (CG; tendon treated with PBS,
n = 4). The collection of adipose tissue was performed
three weeks before the administration of the therapy in
order to obtain an adequate number of MSCs in culture
(Week −3). The tendon lesion was then induced two
weeks before the beginning of the therapy. This time is
enough to consider a consistent lesion at an early stage
(Week −2). Ultrasound examinations were performed
every two weeks until the end of the experiment. After
16 weeks of therapy, a biopsy of the SDFT was per-
formed for histopathological, immunohistochemical and
gene expression evaluations (Week 16). All of the exams
were performed by experimenters blinded to the study
conditions (Figure 1).
Samples from the SDFT of four euthanized horses
with no history of tendonitis (HG, healthy group, n = 4)
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Figure 1 Timeline. US, ultrasound.
Figure 2 Lesion induction image. Lesion induction was guided by
an ultrasound device.
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ween the TG and the CG.
Isolation and cultivation of stem cells
For the collection of adipose tissue, the animals were se-
dated with xylazine (0.7 mg/kg, i.v.). This treatment was
followed by trichotomy, antisepsis and the subcutaneous
injection of 20 mL of 2% lidocaine hydrochloride using
an inverted-L anesthetic block. An approximately 8 cm
long incision was made. This incision was approximately
15 cm abaxial to the spine to allow the visualization of a
layer of fat between the skin and the musculature.
Approximately 2 g of fat was collected per animal. The
fat was immediately packed in a tube containing 50 mL
of Knockout DMEM (Dulbecco’s modified Eagle’s
medium).
The adipose tissue was rinsed with PBS to remove any
contamination with whole blood. This step was followed
by a gentle mechanical separation using a scalpel and
anatomical forceps. Then, 3 mL of type I collagenase di-
luted in 2 mg/mL Knockout DMEM was added to the
mixture. The mixture was then incubated for 12 hours
in a humidified incubator at 37°C with 5% CO2 for the
enzymatic digestion of the adipose tissue. An equal vol-
ume of Knockout DMEM containing 10% fetal bovine
serum (FBS) was then added to the mixture to neutralize
the enzyme action; the mixture was then rinsed with
PBS. The cell pellet obtained from each animal was di-
luted in Knockout DMEM containing 10% FBS and
transferred to 75-cm2 culture plates, which were placed
in an incubator. The culture medium was changed every
48 hours until the culture plate reached 70% confluence.
The trypsinization of the cells was then performed, and
the cells were subjected to the Trypan blue exclusion
test of cell viability. The culture was maintained until
the administration of the cell therapy. Prior to the cellu-
lar implantation, an aliquot of cells (P1) was collected to
perform the immunophenotypic characterization of the
cultured cells. As in a previous study, the following
markers were used in this characterization: CD44, CD90,
CD105 and MHC Class II [23]. Adipogenic, chondroge-
nic and osteogenic differentiations were also performedto demonstrate the multipotent potential of the cells
used (data not shown).
Induction of the tendon lesion
The tendon lesion was induced in the middle region of
the metacarpus (in the central portion of the SDFT) in
one of the forelimbs of the equine, which was randomly
selected, using sterile-filtered collagenase type I (Sigma,
St. Louis, MO, USA). Then, 1,000 U of gel collagenase
was injected into an approximately two-inch-long col-
umn defect in the center of the stress region of the
SDFT, 10 to 12 cm distal to the accessory carpal bone
(ACB). For the correct induction of the lesion, the im-
plantation was guided by an ultrasound device (My Vet
Lab 70, Esaote, Genova, Italy) using a sterile 16-gauge
(G) catheter needle that was manually curved to a 45°
angle (Figure 2) [24]. After the induction of the lesion,
the bandage was tied down to the selected member and
maintained for one week.
Cell therapy
Two weeks after the induction of the lesion (T = week
0), the tendon lesions were treated according to the
treatment protocol of the respective groups using intra-
lesional injections that were guided by ultrasound. The
treated group received 10 × 106 adMSCs, which were
suspended in 1 mL of autologous PC. The collection and
Table 1 Three analyzed categories and their respective
scores in the evaluation of the Power Doppler signals
Category/Score 0 1 2 3
Signal strength No signal Red Orange Yellow
Dark Blue Blue Peacock Blue
Vessel area (mm2) No signal 1 2 to 3 >3
Number of vessels No signal 1 2 to 3 >3
The Power Doppler signal strength was observed in different colors due to
differences in the blood flow direction.
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before the cell implantation using a previously estab-
lished protocol (the platelet activation with calcium hy-
drochloride was not performed) [25]. The numbers of
platelets in the whole blood and PC were counted. Ali-
quots containing 1 mL of PBS for implantation in the
control group were also prepared.
For the administration of the therapy, a local tricho-
tomy was required. This step was followed by anesthetic
block with 2 mL of 2% lidocaine hydrochloride at the
point of the needle insertion and antisepsis. The animals
were also sedated with detomidine (20 μg/kg, i.v.) and
maintained in the catch pen throughout the procedure.
A 21-G needle was used for the administration of the
therapy. The needle was inserted into the center of the
SDFT lesion with the aid of ultrasound. The animals
remained individually confined throughout the experi-
ment, and the selected members remained bandaged for
one week after the therapy.
Clinical evaluation and physical activity
The vital signs of all of the animals were measured for
the evaluation of specific clinical signs, such as local sen-
sitivity, increased temperature and circumference of the
central region of the metacarpus. The animals were also
examined daily for lameness throughout the experiment,
as previously described [26].
 Week 0 to 2: Rest in a stall.
 Week 3 to 5: Walk for 10 minutes, once a day.
 Week 6 to 8: Walk for 10 minutes, twice a day.
 Week 9 to 11: Walk for 20 minutes, once a day.
 Week 12 to 14: Walk for 20 minutes, twice a day.
 Week 13 to 16: Walk for 30 minutes, once a day.
Ultrasonographic evaluation
Ultrasonographic evaluations were performed prior to
the induction of the lesion, before and after the adminis-
tration of the therapy (Week 0), and every 14 days after
the administration of the therapy through the end of the
experiment (Weeks 2, 4, 6, 8, 10, 12, 14 and 16). The
real-time B-mode examination was performed using
ultrasound (My Lab 70, Esaote, Genoa, Italy) equipped
with a 3- to-11 MHz multi-frequency linear trans-
ducer. The lesion regions that received therapy were
also evaluated using Power Doppler to evaluate the
micro-vascularization of the tendon with Doppler fre-
quency of 6.7 MHz, pulse repetition frequency (PRF) of
370 Hz, and wall filter of 3.
The tendon region to be treated for each animal was
determined immediately before the administration of the
therapy, that is, two weeks after the induction of the le-
sion. The larger cross-sectional lesion area over the ap-
proximately 2 cm lesion was used as the criterion.The B-mode ultrasound was used to collect longitu-
dinal images to evaluate the parallelism of the fibers and
to collect cross-sectional images to measure both the
cross-sectional tendon area and the cross-sectional le-
sion area. The percentage of the cross-sectional lesion
area (lesion area/tendon area × 100) was also calculated.
The score used to evaluate the bone vascularity was
adapted for Power Doppler evaluation (Table 1) [27].
This score classification was used to score the three im-
ages obtained in the Power Doppler evaluation videos to
evidence the greatest possible blood flow. The mean
score obtained for each animal at various time points
was calculated, and these data were compared between
the different groups.
Tendon biopsy
The biopsy was performed exactly in the center of the
lesion 16 weeks after the start of the therapy. The ani-
mals were subjected to inhalational anesthesia and re-
ceived 10% xylazine (1.1 mg/kg, i.v.) as premedication.
Diazepam (0.15 mg/kg, i.v.) and ketamine (2.2 mg/kg,
i.v.; Dopalen, Vetbrands, Paulínia, São Paulo, Brazil)
were used for the induction, and isoflurane (Cristália
Chemicals and Pharmaceuticals, Ltd., Itapira, São Paulo,
Brazil) vaporized in 100% oxygen was used for anesthe-
sia maintenance.
The surgical procedures were performed with the ani-
mals in right lateral decubitus. An approximately 2 cm
long incision was made at the exact point of injury (11
to 12 cm ACB) in the skin and subcutaneous tissue until
the SDFT injury was identified. The biopsy was
performed in the central portion of the SDFT; the biopsy
covered the total area of the tendon lesion. After the
correct identification of the injured area, an approxi-
mately 0.5-cm3 sample of the SDFT was collected and
properly stored for subsequent histopathological evalu-
ation, immunohistochemical analysis (in 10% buffered
formalin solution), and RT-PCR (frozen in liquid nitro-
gen) (see Additional file 1: Figure S1). A simple conti-
nuous suture of the paratendon was performed using
Vicryl 2–0 (Ethicon Inc., Johnson & Johnson Medical
Limited, Kirkton Campus, Livingston, West Lothian,
UK), followed by skin suture with simple points separated
with nylon. After the surgical procedure, a compressive
Table 2 Histological and immunohistochemical scoring
system used to grade tendon repair in equines
Variable Score and criterion
Shape of tendon cells 1 = Linear (normal)
2 = Slightly oval
3 = Moderately round
4 = Predominantly round
Density of tendon cells 1 = Sparse (normal)
2 = Slightly increased
3 =Moderately increased
4 = Cell layers
Hemorrhage 1 = Absent (normal)
2 = Sparse or uneven
3 =Multiple areas
4 = Predominantly hemorrhagic
Number of vessels 1 = Normal
2 = Slightly increased
3 =Moderately increased
4 = Severely increased
Inflammatory cell infiltrate 1 = Normal
2 = Slightly increased
3 =Moderately increased
4 = Severely increased
Linearity of collagen fibers 1 = Linear
2 = >50% linear
3 = 20% to 50% linear
4 = Absence of linear areas
Uniformity of collagen fibers 1 = Uniformity of the diameter of all fibers
2 = > 50% of the fibers are uniform
3 = 20% to 50% of the fibers are linear
4 = Complete disorder of the fibers
Collagen type III* 1 = < 10% type III
2 = 10% to 50% type III
3 = > 50% a 90% type III
4 = > 90% type III
Factor VIII* 1 = Average labeling of cells, no
recognition of the vascular structure
2 = Labeling of a few small vessels
3 = Labeling of several small vessels or
greater vessels
4 = Labeling of several great vessels
*Determined from the immunohistochemical analysis.
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dage was changed every 24 hours to dress the wound and
was maintained until the removal of the stitches two
weeks after the surgery. In the immediate postoperative
period, all of the animals were treated with phenylbu-
tazone (4.4 mg/kg, i.v.), which is a non-steroidal anti-
inflammatory drug, on the first day and for the next four
days (2.2 mg/kg, PO q24 h).
Histopathological evaluation
Histological sections were prepared in a longitudinal
paraffin block that was processed using the conventional
paraffinization method. The histological sections were
stained with hematoxylin and eosin (H&E) and Masson’s
trichrome and examined under a light microscope. The
assessor was blinded to the experimental group. Two
histological sections were used in each analysis. The
histopathological analysis was based on scores. All of the
tendon parameters were scored between 1 (normal) and
4 (severe changes): shape of tenocytes, density of teno-
cytes, hemorrhage, neovascularization, inflammatory cell
infiltrate, linearity of collagen fibers, uniformity of colla-
gen fibers and thickness of the epitendon. These assess-
ments were based on those used in previous studies on
tendon repair [4,26].
Immunohistochemical evaluation
The 5-μm-thick cuts obtained from the paraffin blocks
were extended on immunoslides (EasyPath, São Paulo,
SP, Brazil). Prior to incubation with the primary anti-
bodies for collagen type III and factor VIII, the material
was deparaffinized with successive xylene baths and
rinsed three times in absolute alcohol followed by wa-
shes in solutions with decreasing alcohol concentration
(95% and 85%). The antigen retrieval was performed
through enzymatic digestion with 2% pepsin (pH 1.8) for
10 minutes in a 60°C incubator and then for 50 minutes
in a 37°C incubator. The blocking of the endogenous
peroxidase was performed using hydrogen peroxide (3%)
in methanol for 20 minutes, followed by 10 washes with
distilled water. The peroxidase blocking was followed
by the blocking of nonspecific binding with 3% milk
powder for 1 h in a 27°C incubator. The slides were sub-
sequently rinsed with TRIS solution. The primary anti-
bodies were incubated for 18 h (overnight) at 6°C using
polyclonal anti-bovine antibodies for collagen type III
(Novotec, Saint Martin la Garenne, France) and sheep
anti-factor VIII (AbD Serotec, Kidlington, Oxford, UK).
The slides were incubated with the secondary antibody
(EnVision; Dako, Carpinteria, CA, USA) at room tem-
perature for 1 h. The material was then incubated with
DAB (Dako) as chromogen at a dilution of one drop per
mL of solution. The counter-staining was performed
with hematoxylin.To determine the expression of the markers used,
five fields of each fragment, which were given a grad-
uation score ranging from 1 to 4 according to the in-
tensity and abundance of the marking, were assessed
(Table 2).
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The total cellular RNA was purified from tendon tissue
samples using QIA shredder columns (QIAGEN Inc.,
Valencia, CA, USA) and the RNeasy Fibrous Tissue Mini
Kit (QIAGEN Inc.). The purity and relative quality
of the RNA were determined by spectrophotometry
(NanoDrop® 1000 Spectrophotometer, Thermo Scientific™,
Wilmington, DE, USA). All of the RNA samples were
treated with RQ1 purified RQ1 RNase Free DNase
(Promega, Madison, WI, USA) to remove the genomic
DNA from the samples. The first-strand cDNA was syn-
thesized using the SuperScript® VILO™ cDNA Synthesis
Kit (Invitrogen™, Carlsbad, CA, USA).
The relative quantification of the gene expression
in the TG and CG tendons compared with the HG ten-
don was performed using the comparative Ct method
(2−ΔΔCT method) for the relative processing of real-time
PCR data [28], which was obtained with a 7500 Fast
Real-Time PCR System (Applied Biosystems™, Foster City,
CA, USA) and a TaqMan PCR Universal Master Mix II.
The equine primers for type I collagen (COL1A1), type III
collagen (COL3A1), tenascin-C (TNC), tenomodulin
(TNMD), scleraxis (SCX), 18S and β-actin were designed
as previously described [26,29]. COL1A1, COL3A1, TNC,
TNMD and SCX were used as target genes, whereas 18S
and β-actin were used as reference genes.
Each RT-PCR reaction was performed in triplicate and
conducted in a total volume of 20 μL, which contained
0.3 μM of each forward and reverse primers, 0.15 μM of
each probe, 2 μL of the cDNA template, 10 μL of the
master mix, and 6.5 μL of nuclease-free water. Addition-
ally, a “no template” control was included in triplicate
on each plate. The following PCR conditions were used:
initial denaturation at 95°C for 10 minutes and 40 cycles
at 95°C for 15 s and 60°C for 1 minute. The data analysis
was performed through the normalization of the ampli-
fied value of each target gene with the arithmetic mean
of the threshold cycle (CT) of the corresponding en-
dogenous control. A sample of the HG was selected for
calibration and used on each plate. The gene expression
of the target genes in the TG and CG was calculated
relative to that in the HG.
Statistical analysis
For the ultrasonographic evaluation, the mixed model
repeated measures design (PROC MIXED, SAS Institute
Inc., Cary, North Carolina, USA) was used to compare
the average lesion percentage or the average lesion area
between the experimental groups and time points. The
initial time (Week 0) was also used as a reference for the
comparison of the different time points within a group.
An interaction term between the treatment and the time
point was included to test the hypothesis that the differ-
ence between treatments was time-dependent. Tukey’smethod was used to adjust the P-values that resulted
from the multiple comparisons. An autoregressive co-
variance structure was used to model the repeated mea-
sures in the same animal. The Wilcoxon test (PROC
NPAR1WAY, SAS Institute Inc., Cary, North Carolina,
USA) was used to compare the median score of
echogenicity of each time point between treatments.
In the histopathological evaluation, the Wilcoxon test
(PROC NPAR1WAY, SAS Institute Inc., Cary, North
Carolina, USA) was used to compare the average sum of
the scores between the different groups. In the immuno-
histochemical evaluation, the Wilcoxon test (PROC
NPAR1WAY, SAS Institute Inc., Cary, North Carolina,
USA) was used to compare the median score between
the different treatments. We also used the Wilcoxon test
(PROC NPAR1WAY, SAS Institute Inc., Cary, North
Carolina, USA) for the statistical evaluation of the rela-
tive gene expression of COL1A1, COL3A1, TNC, TNMD
and SCX between the TG and the CG. The Wilcoxon
test was also used to compare the RNA concentration
obtained between the different groups.
Results
Animals
One of the animals of the control group died during the
course of the experiment due to causes unrelated to the
study; this death decreased the number of animals in
our experiment.
Isolation and cultivation of adMSCs
Approximately 2 g of adipose tissue was collected from the
selected animals. No problems were encountered with the
healing of the wound located on the back of the animals.
A cell cultivation time of three weeks was sufficient for the
expansion of the necessary number of adMSCs (10 × 106)
for the cell therapy on the first pass (P1). After five days of
culture, the number of viable stem cells ranged from 3 ×
106 to 6 × 106 (mean = 4 × 106), with a cell viability greater
than 96% in all of the samples. After 21 days of cell culture,
the number of viable cells ranged from 14 × 106 to 22 ×
106 (mean 16 × 106), with a cell viability greater than 98%.
Cell therapy and clinical evaluation
The implantation of 10 × 106 equine adMSCs suspended
in platelet concentrate and the intralesional injection of
PBS was successfully performed in all of the animals.
The platelet concentration in the whole-blood samples
ranged from 110 × 103 platelets/μL to 171 × 103 plate-
lets/μL (mean = 121 × 103 platelets/μL). The autologous
platelet concentrate used for the suspension of the MSCs
derived from adipose tissue was successfully obtained in
all of the samples; the platelet concentration ranged from
305 × 103 platelets/μL to 377 × 103 platelets/μL (mean =



































































Figure 3 Ultrasonographic measurements. A) Relationship
between the lesion area in the treated and the control groups at
different time points after therapy. B) Relationship between the
percentage of the cross-sectional lesion area in the different groups
at different time points after therapy.
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leukocytes/μL).
There was no change in any of the clinical parameters
of the animals during the experiment, and there was no
difference in the sensitivity, the temperature and the cir-
cumference of the central metacarpal area, as well as the
presence of lameness, between the different experimen-
tal groups.
Ultrasonographic evaluation
The results of the statistical modeling suggested that
there was a time-dependent difference in the cross-
sectional lesion area and its percentage between the
treatments (P = 0.02 and 0.002 for the interaction be-
tween treatments and time points, respectively). How-
ever, the comparisons between the treatments made
within each time point revealed no significant diffe-
rences (Figure 3). The figure shows that the cross-
sectional lesion area and its percentage in the TG
remained constant and then decreased. The figure also
shows that there was an increase in the cross-sectional
lesion area and its percentage in the CG at Weeks 2, 4
and 6 (Figure 4). This increase was followed by a subse-
quent decrease. A different data analysis observed the
evolution of the cross-sectional lesion area and its per-
centage in the TG and the CG between the time of treat-
ment administration (Week 0) and the other studied
time points. The analysis showed that the CG had a
significant difference between Week 0 and Week 4
(cross-sectional lesion area, P = 0.0002; percentage of
cross-sectional lesion area, P = 0.0003) and between Week
0 and Week 6 (cross-sectional lesion area, P = 0.001, per-
centage of cross-sectional lesion area, P = 0.022), whereas
the TG did not show any differences (Figure 3).
The analysis of the sum of the scores used for the
evaluation of Power Doppler revealed no significant dif-
ference between the treatments (P = 0.097). However,
when the different assessed time points were individually
compared, an increased blood flow was observed in the
TG compared with the CG at Week 6 (P = 0.05; Figures 5
and 6).
Histopathological evaluation
The longitudinal histopathological specimens stained
with H&E and Masson trichrome were analyzed and
classified according to pre-established scores. Based on
the analysis method used, a normal tendon would obtain
a score of 8, whereas a tendon with maximum-severity
histopathological damage would obtain a score of 32.
The sum of the scores in the TG (14.75 ± 2.98) was sig-
nificantly lower (P = 0.049) than the sum of the scores in
the CG (22.66 ± 2.51). Overall, the TG exhibited bet-
ter score results of the linearity of the collagen fibers
(P = 0.04), compared with the CG. Among the individualvariables assessed in the histopathological evaluation, the
presence of inflammatory cell infiltrates showed the lar-
gest difference between the groups (P = 0.03): the treated
group (mean = 2 ± 2.0) exhibited better results compared
with the control group (mean = 3.66 ± 0.57; Figure 7).
Immunohistochemical evaluation
The distribution and intensity of the labeling of collagen
type III and factor VIII were scored in the cross-sections.
No significant differences were observed in the scores
given to the marking of collagen type III and factor
VIII between the different groups (see Additional file 2:
Figure S2).
RNA purification and qRT-PCR
The RNA quality obtained from all of the tendon sam-
ples from all of the groups was assessed by a spectro-
photometer at 260:280 nm (data not show). The RNA in
the samples exhibited median concentrations of 161.85 ±
54.74 ng/μL in the TG, 132.4 ± 90.1 ng/μL in the CG, and
67.35 ± 31.05 ng/μL in the HG. The evaluation of the gene
expression found no difference in the expression of the
anabolic genes (COL1A1, COL3A1 and TNC) between
the different groups, but a trend higher (P = 0.08)
Figure 4 Transverse ultrasound images. The images were obtained 12 cm distal to the accessory carpal bone, six weeks after therapy.
A) Treated group. B) Control group.
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There was no difference in the expression of the phe-
notypic genes (SCX and TNMD) between the different
groups (see Additional file 3: Table S1).Discussion
The histopathological evaluation revealed that the ad-
ministered therapy resulted in a better organization of
collagen fibers and a decreased inflammatory infiltrate.
The ultrasound evaluation showed a lack of lesion pro-
gression (lesion area). An increased number and in-
tensity of the signals detected by the Power Doppler
examination was observed; this result evidenced the





















































Figure 5 Power Doppler evaluations. Relationship between the Power D
times point after therapy.the TG. The therapy used did not result in any diffe-
rences in the expression levels of any of the genes tested.
Tendon lesions can be induced by different methods.
These techniques are basically divided into physical
and enzymatic methods, such as the use of collage-
nase [4,5,8,13], collagenase gel [24,26], and surgical
induction [30]. Although several studies have been
conducted on the subject, there is still no consensus
on which is the best induction technique [31]. The
tendon lesion resulting from the use of collagenase
for the induction of tendonitis is not identical to the
lesion resulting from the etiopathogenesis of a naturally
occurring injury. However, the collagenase method ex-
hibits several advantages over the other methods, such as





oppler scores in the treated group and control group at different
Figure 6 Cross-sectional image of the Power Doppler
ultrasonographic cross-sectional evaluation. The images were
obtained 12 cm distal to the accessory carpal bone six weeks after
therapy. A) Treated group: vessel area = 3 mm2, signal strength = 2,
number of vessels = 1. B) Control group: vessel area = 1 mm2, signal
strength = 1, number of vessels = 1.
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creased vascularization, and the absence of inflammation
mediated by inflammatory cells in the injured tendon [32].
The results obtained from the induction of the tendon le-
sion using collagenase gel are consistent with those
reported previously [24]: it was possible to create consist-
ent lesions, and there was minor extravasation of the en-
zyme to the epitendon.Figure 7 Histopathological image of the superficial digital flexor tend
hematoxylin & eosin (H&E) using a 20× objective. A) Healthy group: health
MSCs derived from adipose tissue and platelet concentrate. C) Control gro
a tenocyte and the black arrow indicates the presence of inflammatory celThe collection of adipose tissue, although considered
an invasive procedure, proved to be a relatively simple
technique [4,5,23], and no postoperative complications
were observed in the animals. The isolation of the stromal
vascular fraction and the subsequent culture of adMSCs
until a sufficient amount was obtained (approximately
10 × 106 MSCs) for the implementation of the stem cell
therapy were successfully achieved during the three week
period used in this experiment. Although the quantifica-
tion of the cell duplication of adMSCs was not performed
in the present study, the data obtained are consistent with
the results previously described in studies that reported
the rapid growth of these cells in culture, which enables
the generation of a higher concentration of progenitor
cells in a shorter period of time [17,33].
Some studies that use MSCs derived from bone mar-
row for the therapy of equine tendonitis use a marrow
puncture to isolate the bone marrow supernatant to sus-
pend the stem cells at the time of the therapy. There are
reports of beneficial effects from this type of therapeutic
combination due to the improvement in the therapeutic
effect of the progenitor cells that is induced by the
stimulant effects of the bone marrow supernatant [34].
In addition to the bone marrow supernatant [15,35],
progenitor cells have been previously suspended in PBS
[3,4,13], cell culture medium [26], autologous serum
[5,10], plasma [6], and platelet-rich plasma [11]. In the
present study, we chose to prepare the stem cell suspen-
sion in PC to combine the therapeutic effects of MSCs
derived from the adipose tissue with the growth factors
that are released by platelets after their activation. Our
use of double centrifugation for the collection of the PC
proved effective and enabled the collection of a PC with
an average platelet number that was greater than that
reported by previous studies [14,25].
Although the PC was not activated in this study, there
is clinical evidence that demonstrates an improvement
in tendon repair after therapy using a non-activated PCon. The figures show histopathological specimens stained with
y tendon. B) Treated group: tendon treated with the combination of
up: tendon treated with PBS (the white arrow indicates the presence of
ls).
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activated PC can be explained by the in situ activation of
platelets and the subsequent release of growth factors
due to its stimulation by the components present in the
local environment (for example, collagen) [36]. The acti-
vation of platelets can be induced by several methods. A
recent study in horses showed that CaCl2 induced the
highest concentration of growth factors compared with
the other various types of platelet activators tested. How-
ever, we chose to not exogenously activate the platelet
concentrate prior to the tendon therapy due to our uncer-
tainty of the safety of its use in vivo [18].
The therapy adopted in this study, which was followed
by rest with gradual increases in physical activity, was
proven feasible. There were no episodes of lameness or
sensitivity in the tendon after the administration of the
therapy. Some researchers believe that physical activity,
when correctly and gradually applied, can result in de-
creased tendon recovery time [11].
The results of the clinical assessment are consistent
with the results obtained in previous studies: there was
no difference in the sensitivity and the average circum-
ference of the central portion of the metacarpal region
between the groups [5]. There was also no difference in
the degree of lameness between the groups [26]. The
ultrasound evaluation revealed improvement of the
cross-sectional lesion area and its percentage in the TG
compared with the CG. This result is consistent with
previous studies that used MSCs for the therapy of
equine tendonitis [8,10,37]. The lack of significant differ-
ences between the cross-sectional lesion area and its
percentage at different time points after the therapy can
be justified by the correction of the P-values resulting
from Tukey’s test and by the accidental reduction of the
size of the CG.
The interpretation of the evolution of the cross-
sectional lesion area and its percentage in the TG and
the CG between the time of therapy (Week 0) and the
subsequent assessment times shows significant differen-
ces between the groups at Weeks 4 and 6. This result
demonstrated that the therapy used in this study ex-
hibited a preventive action on the progression of the
lesion because the TG showed no increase in the cross-
sectional lesion area or its percentage (Figure 3).
This absence of lesion progression can be largely
explained by the anti-inflammatory and immunomodula-
tory action of the therapy [38,39]. We hypothesize that
the moment of therapy administration may have con-
tributed to these data because the preventive action of
the therapy on the progression of the tendon lesion in
the TG can be more clearly demonstrated in the ultra-
sound evaluation (the tendon lesion is not yet fully de-
veloped at this point). If the therapy had been performed
four weeks after the induction of the lesion, we wouldcertainly not find this preventive action because the le-
sion would have already reached its maximum size. This
statement is based on a recent study that used a tech-
nique similar to the induction of tendon injury with the
collagenase gel that was used in the present study. The
study demonstrated that the maximal cross-sectional area
of the lesion and the maximal relative cross-sectional area
of the lesion of the SDTF are found four weeks after lesion
induction [24].
The use of Color Doppler ultrasound for the assess-
ment of the vascularization in equine tendonitis [40] and
after therapy for equine tendonitis with PC [19] has been
described. Although Power Doppler does not provide in-
formation on the blood flow speed or direction, as can
be obtained with the Color Doppler ultrasound, Power
Doppler has a greater sensitivity to the presence of blood
and to the blood volume, which enables the visualization
of smaller vessels [27]. The results of the assessment of
the vascularization obtained in this study indicate that
there was increased blood flow in the treated group six
weeks after the start of the therapy compared with the
control group (P = 0.05). This result suggests that a biopsy
at Week 6 would more likely find a larger number of ves-
sels in the treated group than in the control group; this
would be true in both the histopathological analysis and
the immunohistochemical evaluation using factor VIII.
The vessels are poorly visualized with the Color Doppler
evaluation of a healthy digital flexor tendon. Hypervascu-
larity is expected during the tissue repair process, but
there is decreased vascularity with the progress of tendon
repair [40].
The semi-quantitative morphological evaluation de-
monstrated the histopathological improvement of the
treated group compared to the control group; this
improvement is based on the cumulative sum of histo-
logical scores (P = 0.049). This evaluation also demon-
strated a reduction in the inflammatory infiltrate and an
improved organization of the ECM. These data are in
agreement with previously reported results [4,5,13]. An
improved linearity and uniformity of the collagen fibers
was also observed in the treated group compared with
the control group.
The action of the anti-inflammatory therapy is evident
after combining the analysis of the histopathological data
with the ultrasound evaluation (Weeks 2, 4 and 6). The
cross-sectional area and its percentage did not worsen
with therapy in the TG (Weeks 2, 4 and 6), whereas
there was an increase in the lesion in the same period in
the CG. This result suggests a possible anti-inflammatory
effect on the progression of the lesion that prevents it
from increasing in size by either minimizing or stabilizing
the degeneration of the tendon fibers. The decreased in-
flammation after the implantation of adMSCs is likely due
to the immunosuppressive effect of these cells [39,41,42].
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inflammatory effects of MSCs that benefit tendon repair;
these include an increase in chemokines, the suppression
of cytokine secretion from dendritic cells, and a reduction
in the effects of T lymphocytes and natural killer cells.
These data highlight the potent anti-inflammatory and im-
munosuppressive effects of these cells. Given these potent
immunomodulatory effects of MSCs, it is not surprising
that these cells are being used in clinical studies of graft-
versus-host disease, which is usually a fatal condition after
organ transplantation [43].
The immunohistochemical evaluation found no diffe-
rence in the expression of collagen type III and factor
VIII between the different groups. Previous studies have
described the use of mononuclear cells derived from
adipose tissue and adMSCs for the therapy of equine
tendonitis. These studies have demonstrated a decreased
expression of type III collagen in the treated group [4,5].
In addition, another study described the quantification
of the blood vessels present in the SDFT treated with
PC using factor VIII [19]: a greater amount of vessels
was found in the group that received therapy with a
platelet concentrate. Factor VIII is a clotting pro-cofactor
that is found only on intact and functional endothelial
cells of blood vessels; thus, this factor is an important tool
for the evaluation of tissue vascularization [44].
The increased expression of the COL1A1, COL3A1,
TNC, TNMD and SCX genes in the tendons of the TG
and the CG compared with the HG are consistent with
the results obtained in a previous study [24]. Soon after
tendon injury occurs, the expression levels of COL1A1
and COL3A1 increased [45]. The expression level of
TNC, which is an ECM protein that is synthesized
during inflammation and tissue remodeling [46] and
modulates the binding of cells to ECM components, also
increased [47]. TNMD regulates the proliferation of
tenocytes and the maturation of collagen fibers [48]. The
increased expression of SCX in the injured tendons was
consistent with the attempt to repair the tissue because
this gene regulates the tendon progenitor cells [49] and
is a marker of tendon and ligament development [49].
Although an increases expression of the tested genes
was observed in the injured tendons (TG and CG) com-
pared with the healthy tendons (HG), no difference was
observed between the expression in the different injured
groups (TG and CG). This result is consistent with the
results obtained in previous studies [13,26]. However, a
trend for increases in the expression of COL3A1 was ob-
served in the control group (P = 0.08). Soon after tendon
injury, the gene expression levels of collagen type I and
III increase. The decrease in the concentration of col-
lagen type I compared with that of collagen type III is
more closely related to the formation of scar tissue than
to tendon regeneration [26]. Thus, the lower expressionof the COL3A1 gene in the treated group suggests that
the tendons in the TG are better repaired than those in
the CG. However, this result should be examined with
caution because the difference in the expression levels of
COL3A1 between the groups was not significant and
because no increase in the collagen type III protein
expression was observed in the immunohistochemical
evaluation.
Only one study has reported differences in gene expres-
sion after the use of cell therapy for equine tendonitis.
This study reported an increase in the expression of the
gene cartilage oligomeric matrix protein (COMP) after
tendonitis therapy with mononuclear cells derived from
adipose tissue [4]. A likely explanation for the lack of gene
expression differences between the tendons of the TG,
which exhibited improved histological and ultrasound
characteristics, and the tendons of the CG is that the
tested genes, although associated with tendon repair, are
not specific. Thus, further research is necessary to select
genes that are better markers of tendon repair [50,51].
A limitation of the present study was the fact that the
investigation did not determine the exact mechanism of
action of the therapy that was used. This lack could have
been due to trophic action (local modulation of cyto-
kines), the replacement of cells from the injured tissue,
local immunomodulation, or other mechanisms that
favor the improvement of tissue repair evidenced by
histopathological and ultrasound analyses.
There is great difficulty in the development of a well-
designed large-scale study involving equines. The lack of
basic knowledge of the behavior of adult stem cells and
PC after their administration is also undeniable. Progeni-
tor cells are believed to differentiate in the specific tissue
site into which they were deployed (for example, tenocyte
differentiation) and thus promote the production of the
appropriate ECM. These cells can also synthesize bioactive
proteins (for example, growth factors and cytokines) that
promote the recruitment of endogenous stem cells and
the anabolic stimulation of newly recruited cells and the
mature cells of the tissue itself [16].
Similar to other experiments that used cell therapy with
or without PC for the treatment of equine tendonitis
[4-8,11,13,26], the present study demonstrated a satisfac-
tory result. However, it has limitations regarding the effects
of the therapy used. The results demonstrate that there is
no definition for the effectiveness of a therapy for the treat-
ment of equine tendonitis. Based on the preventive result
obtained with the adMSCs suspended in PC on the pro-
gression of the lesion in the ultrasound evaluation (cross-
sectional lesion area and its percentage), further studies
should be conducted to confirm this preventive action and
the mechanism of action of the therapeutic association, as
well as the action of progenitor cells and platelets alone as
the lesion progresses. This conclusion is consistent with
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that prevention can have a significantly greater clinical im-
pact than therapy due to the impossibility of tendon regen-
eration [52].
Future studies should be conducted to further elucidate
the ideal time of administration of the equine tendonitis
therapy, which is currently standardized between 7 and
45 days after the onset of the lesion. Additionally, further
studies would contribute to the understanding of when
the best therapeutic results are obtained and whether it
really is possible to prevent further injury when the ther-
apy is administered to a still-developing injury.
Basic studies that elucidate the real mechanism of action
of the therapy used in tissue repair should also be
conducted to confirm the differentiation of the stem cells
used, analyze the release of trophic factors (for example,
cytokines and growth factors), and verify the anti-
inflammatory and immunomodulatory action of the ther-
apy. Better knowledge of the etiopathogenesis of tendonitis
associated with the knowledge of the mechanism of action
of adult stem cells and activated platelets will enable im-
proved clinical outcomes and result in the verification of
the therapeutic efficacy of this new biotechnology.
Conclusions
The present study demonstrated that the use of adMSCs
combined with PC had a favorable action in the therapy
of tendonitis. This result was verified mainly by the
prevention of the progression of the lesion, which was
observed in the ultrasound evaluation, and by the sig-
nificant improvement observed in the histopathological
analysis scores. Future studies should be conducted to elu-
cidate the immunomodulatory action of adMSCs com-
bined with PC and the best time for its administration.
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Additional file 1: Figure S1. Biopsy of the superficial digital flexor
tendon (SDFT). A) Isolation of SDFT in the central metacarpal region of
forelimb, 10 to 11 cm distal to the accessory carpal bone. B) Biopsy of
the lesion area in the center of the SDFT.
Additional file 2: Figure S2. Immunohistochemical image of the
superficial digital flexor tendon. A) Immunohistochemical image for
collagen III, treated group, 40× objective. B) Immunohistochemical image
for collagen type III, control group, 40× objective. C) Immunohistochemical
image for factor VIII, treated group, 20× objective. D) Immunohistochemical
image for factor VII, control group, 20× objective.
Additional file 3: Table S1. Gene expression. Median of the gene
expression levels in the different groups relative to the gene expression
levels obtained in healthy tendons.
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